Scrip
>>Focus On Asia

Shionogi Moves To Build Pipeline Amid Progress Challenges

Obesity, Pain Assets Highlighted At R&D Day

20 Oct 2022

Shionogi unveiled its latest pipeline update, including a focus on long-standing key areas such as HIV and COVID-19 and a new obesity candidate, at its recent R&D Day, amid struggles to line up new products for launch over the next few years. The Japanese firm also seems set to seek further in-licencing collaborations.

Shionogi announced its R&D strategy while admitting struggle for new candidates — Shionogi updates R&D strategy while admitting struggle for new candidates • Source: Shutterstock

While preparing to submit the highly anticipated Phase III results for it oral COVID-19 antiviral Xocova (ensitrelvir; S-217622), Shionogi & Co. Ltd. is facing a struggle to line up other candidates for launch over the next few years.

At its recent R&D Day event, CEO Isao Teshirogi conceded the Japanese firm has been facing “a huge challenge” in...